← Leaderboards
Wenchao Song
University Of Pennsylvania
$30,516,555
Attributed
$33,448,247
Total exposure
17
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,448,247 · 17
By mechanism
R01$32,073,342 · 13
R21$1,374,905 · 4
Top collaborators
- Edward A Miao6 shared
- Jacob Brenner4 shared
- Vladimir R Muzykantov4 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Vladimir R Muzykantov$31,969,177
- Jacob Brenner$6,438,045
- Michael P Madaio$4,636,695
- Mariusz Z Ratajczak$9,429,196
- John Patterson Atkinson$19,338,397
Others in their field
Top investigators on “Complement”
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$128,874,888
- Wafaa M. El-Sadr · Columbia University Health Sciences$101,800,876
- Myron S Cohen · Family Health International$101,800,876
- Steve Riordan · Westat, Inc.$94,143,268
- David R. Weir · University Of Michigan At Ann Arbor$93,718,087
- Stuart L Schreiber · Harvard University (Medical School)$88,512,978
Research focus
ComplementComplement ActivationPreventTissuesMediatingPlayPathogenesisMouse ModelPathway InteractionsInjuryIn VivoHost DefenseInflammatoryComplement 5aCellsProteinsAlternative Complement PathwayLeadPathologyPharmaceutical PreparationsMediator Of Activation ProteinComplement 3aLightProperdin
Grant awards (84)
Controlling complement to unleash nanomedicine for acute critical illnesses$695,095
R01 · FY2025 · HL
Complement in Pathogenesis and Experimental Therapy of ANCA Disease$729,914
R01 · FY2024 · AI · contact PI
Controlling complement to unleash nanomedicine for acute critical illnesses$681,194
R01 · FY2024 · HL
MASPs as therapeutic targets in complement-mediated diseases$573,810
R01 · FY2024 · AI · contact PI
Complement in Pathogenesis and Experimental Therapy of ANCA Disease$729,914
R01 · FY2023 · AI · contact PI
Controlling complement to unleash nanomedicine for acute critical illnesses$695,095
R01 · FY2023 · HL
MASPs as therapeutic targets in complement-mediated diseases$573,810
R01 · FY2023 · AI · contact PI
Complement and efferocytosis in clearing pyroptotic cells$455,562
R01 · FY2023 · AI
Complement in Pathogenesis and Experimental Therapy of ANCA Disease$729,914
R01 · FY2022 · AI · contact PI
Controlling complement to unleash nanomedicine for acute critical illnesses$626,215
R01 · FY2022 · HL
MASPs as therapeutic targets in complement-mediated diseases$581,935
R01 · FY2022 · AI · contact PI
Complement and efferocytosis in clearing pyroptotic cells$455,562
R01 · FY2022 · AI
Complement in Pathogenesis and Experimental Therapy of ANCA Disease$729,914
R01 · FY2021 · AI · contact PI
MASPs as therapeutic targets in complement-mediated diseases$573,222
R01 · FY2021 · AI · contact PI
Complement and efferocytosis in clearing pyroptotic cells$455,607
R01 · FY2021 · AI
Complement in Pathogenesis and Experimental Therapy of ANCA Disease$727,668
R01 · FY2020 · AI · contact PI
MASPs as therapeutic targets in complement-mediated diseases$580,145
R01 · FY2020 · AI · contact PI
Complement and efferocytosis in clearing pyroptotic cells$376,282
R01 · FY2020 · AI
Complement and efferocytosis in clearing pyroptotic cells$68,101
R01 · FY2020 · AI
Complement and efferocytosis in clearing pyroptotic cells$455,471
R01 · FY2019 · AI
Complement dysregulation and atypical hemolytic uremic syndrome$400,000
R01 · FY2019 · AI · contact PI
Pathogenesis and therapy of dense deposit disease in a mouse model$400,000
R01 · FY2019 · AI · contact PI
Complement dysregulation and atypical hemolytic uremic syndrome$400,000
R01 · FY2018 · AI · contact PI
Pathogenesis and therapy of dense deposit disease in a mouse model$400,000
R01 · FY2018 · AI · contact PI
Complement dysregulation and atypical hemolytic uremic syndrome$400,000
R01 · FY2017 · AI · contact PI
Pathogenesis and therapy of dense deposit disease in a mouse model$400,000
R01 · FY2017 · AI · contact PI
Membrane complement regulators in RPE degeneration and retinal injury$503,645
R01 · FY2016 · EY · contact PI
Pathogenesis and therapy of dense deposit disease in a mouse model$400,000
R01 · FY2016 · AI · contact PI
Complement dysregulation and atypical hemolytic uremic syndrome$400,000
R01 · FY2016 · AI · contact PI
Membrane complement regulators in RPE degeneration and retinal injury$493,571
R01 · FY2015 · EY · contact PI
Complement dysregulation and atypical hemolytic uremic syndrome$400,000
R01 · FY2015 · AI · contact PI
Pathogenesis and therapy of dense deposit disease in a mouse model$400,000
R01 · FY2015 · AI · contact PI
Membrane complement regulators in RPE degeneration and retinal injury$493,571
R01 · FY2014 · EY · contact PI
Biology of decay accelerating factor$379,462
R01 · FY2014 · AI · contact PI
Complement and allergic asthma$200,000
R21 · FY2014 · AI · contact PI
A murine model for human factor H R1210C mutation-related diseases$200,000
R21 · FY2014 · AI · contact PI
Membrane complement regulators in RPE degeneration and retinal injury$503,645
R01 · FY2013 · EY · contact PI
Mechanism of action and therapeutic targeting of properdin in complement injury$364,918
R01 · FY2013 · AI · contact PI
Biology of decay accelerating factor$357,148
R01 · FY2013 · AI · contact PI
A murine model for human factor H R1210C mutation-related diseases$240,000
R21 · FY2013 · AI · contact PI
Complement and allergic asthma$240,000
R21 · FY2013 · AI · contact PI
Mechanism of action and therapeutic targeting of properdin in complement injury$388,438
R01 · FY2012 · AI · contact PI
Biology of decay accelerating factor$380,412
R01 · FY2012 · AI · contact PI
Regulation of Toll-like receptor signaling by complement$313,632
R01 · FY2012 · GM · contact PI
Mechanism of action and therapeutic targeting of properdin in complement injury$388,658
R01 · FY2011 · AI · contact PI
Biology of decay accelerating factor$380,866
R01 · FY2011 · AI · contact PI
Complement regulatory proteins and autoimmune disease$378,583
R01 · FY2011 · AI · contact PI
Regulation of Toll-like receptor signaling by complement$313,632
R01 · FY2011 · GM · contact PI
Development of small molecule inhibitors human altrenative pathway complement$192,530
R21 · FY2011 · AI · contact PI
Mechanism of action and therapeutic targeting of properdin in complement injury$392,205
R01 · FY2010 · AI · contact PI
Biology of decay accelerating factor$384,970
R01 · FY2010 · AI · contact PI
Complement regulatory proteins and autoimmune disease$382,407
R01 · FY2010 · AI · contact PI
Regulation of Toll-like receptor signaling by complement$316,800
R01 · FY2010 · GM · contact PI
Complement regulatory proteins and autoimmune disease$386,269
R01 · FY2009 · AI · contact PI
Mechanism of protection of DAF and CD59 in SLE$368,577
R01 · FY2009 · AI · contact PI
Biology of decay accelerating factor$331,721
R01 · FY2009 · AI · contact PI
Regulation of Toll-like receptor signaling by complement$318,333
R01 · FY2009 · GM · contact PI
Complement regulatory proteins and autoimmune disease$386,269
R01 · FY2008 · AI · contact PI
Mechanism of protection of DAF and CD59 in SLE$368,577
R01 · FY2008 · AI · contact PI
Biology of decay accelerating factor$331,721
R01 · FY2008 · AI · contact PI
Complement regulatory proteins and autoimmune disease$393,333
R01 · FY2007 · AI · contact PI
Mechanism of protection of DAF and CD59 in SLE$375,716
R01 · FY2007 · AI · contact PI
Biology of decay accelerating factor$338,145
R01 · FY2007 · AI · contact PI
Mechanism of protection of DAF and CD59 in SLE$386,938
R01 · FY2006 · AI · contact PI
Biology of decay accelerating factor$348,245
R01 · FY2006 · AI · contact PI
Complement Regulatory Proteins and Autoimmune Disease$309,551
R01 · FY2006 · AI · contact PI
Molecular Pharmacology of Estrogen Sulfotransferase$278,595
R01 · FY2006 · HD · contact PI
Mechanism of protection of DAF and CD59 in SLE$396,250
R01 · FY2005 · AI
Biology of decay accelerating factor$356,625
R01 · FY2005 · AI
Complement Regulatory Proteins and Autoimmune Disease$317,000
R01 · FY2005 · AI
Molecular Pharmacology of Estrogen Sulfotransferase$285,300
R01 · FY2005 · HD
Complement Regulatory Proteins and Autoimmune Disease$317,000
R01 · FY2004 · AI
Molecular Pharmacology of Estrogen Sulfotransferase$285,300
R01 · FY2004 · HD
BIOLOGY OF DECAY ACCELERATING FACTOR$277,375
R01 · FY2004 · AI
Complement Regulatory Proteins and Autoimmune Disease$317,000
R01 · FY2003 · AI
Molecular Pharmacology of Estrogen Sulfotransferase$285,300
R01 · FY2003 · HD
BIOLOGY OF DECAY ACCELERATING FACTOR$277,375
R01 · FY2003 · AI
Molecular Pharmacology of Estrogen Sulfotransferase$313,065
R01 · FY2002 · HD
BIOLOGY OF DECAY ACCELERATING FACTOR$235,769
R01 · FY2002 · AI
Complement Regulatory Proteins and Autoimmune Disease$132,083
R01 · FY2002 · AI
Complement Regulatory Proteins and Autoimmune Disease$302,375
R21 · FY2001 · AI
BIOLOGY OF DECAY ACCELERATING FACTOR$277,375
R01 · FY2001 · AI
BIOLOGY OF DECAY ACCELERATING FACTOR$277,375
R01 · FY2000 · AI
ROLE AND REGULATION OF ESTROGEN SULFOTRANSFERASE$190,167
R01 · FY2000 · HD